DK0687300T3 - LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation - Google Patents

LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation

Info

Publication number
DK0687300T3
DK0687300T3 DK94909270T DK94909270T DK0687300T3 DK 0687300 T3 DK0687300 T3 DK 0687300T3 DK 94909270 T DK94909270 T DK 94909270T DK 94909270 T DK94909270 T DK 94909270T DK 0687300 T3 DK0687300 T3 DK 0687300T3
Authority
DK
Denmark
Prior art keywords
proliferation
cd2a antibody
inhibiting
cell activation
cd2a
Prior art date
Application number
DK94909270T
Other languages
Danish (da)
English (en)
Inventor
Herve Bazin
Dominique Latinne
Original Assignee
Univ Catholique Louvain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Catholique Louvain filed Critical Univ Catholique Louvain
Application granted granted Critical
Publication of DK0687300T3 publication Critical patent/DK0687300T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK94909270T 1993-03-05 1994-03-04 LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation DK0687300T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2700893A 1993-03-05 1993-03-05
US11903293A 1993-09-09 1993-09-09
PCT/IB1994/000043 WO1994020619A1 (en) 1993-03-05 1994-03-04 LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T-CELL ACTIVATION AND PROLIFERATION

Publications (1)

Publication Number Publication Date
DK0687300T3 true DK0687300T3 (da) 2001-12-31

Family

ID=26701922

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94909270T DK0687300T3 (da) 1993-03-05 1994-03-04 LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation

Country Status (10)

Country Link
EP (1) EP0687300B1 (ja)
JP (2) JP3711143B2 (ja)
AT (1) ATE205531T1 (ja)
AU (1) AU686600B2 (ja)
CA (1) CA2157500C (ja)
DE (1) DE69428272T2 (ja)
DK (1) DK0687300T3 (ja)
ES (1) ES2164699T3 (ja)
PT (1) PT687300E (ja)
WO (1) WO1994020619A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
DK0959899T3 (da) * 1996-08-16 2009-09-07 Biotransplant Inc LO-CD2a-antistof samt dets anvendelse til h mning af T-celleaktivering og -proliferation
AU750891B2 (en) 1996-12-06 2002-08-01 Aventis Pharmaceuticals Inc. Polypeptides encoded by a human lipase-like gene, compositions and methods
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
JP4808841B2 (ja) * 1997-07-18 2011-11-02 バイオトランスプラント,インコーポレイテッド T細胞活性化および増殖を阻害するLO−CD2a抗体およびその使用法
US6558662B2 (en) 1997-11-14 2003-05-06 The General Hospital Corporation Treatment of hematologic disorders
CA2497628A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
KR101240206B1 (ko) 2010-10-05 2013-03-06 고려대학교 산학협력단 자연살상 세포-매개 면역반응 억제용 조성물
CN111670200A (zh) * 2017-11-29 2020-09-15 美真达治疗公司 用于耗尽cd2+细胞的组合物和方法
WO2020216947A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381292A (en) * 1980-11-14 1983-04-26 The Board Of Trustees Of The Leland Stanford Jr. University Anti-human T-lymphocyte monoclonal antibody

Also Published As

Publication number Publication date
JP4195453B2 (ja) 2008-12-10
ES2164699T3 (es) 2002-03-01
AU6218194A (en) 1994-09-26
CA2157500C (en) 2005-08-16
CA2157500A1 (en) 1994-09-15
AU686600B2 (en) 1998-02-12
WO1994020619A1 (en) 1994-09-15
PT687300E (pt) 2002-03-28
ATE205531T1 (de) 2001-09-15
DE69428272T2 (de) 2002-06-27
JP2005239725A (ja) 2005-09-08
EP0687300B1 (en) 2001-09-12
JPH08507438A (ja) 1996-08-13
JP3711143B2 (ja) 2005-10-26
DE69428272D1 (de) 2001-10-18
EP0687300A1 (en) 1995-12-20

Similar Documents

Publication Publication Date Title
DK1003552T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
NO962346L (no) Humaniserte antistoffer og anvendelser derav
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
DE69433406T2 (de) Antikörper gegen cd40
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
GR3026419T3 (en) Inducing antibody response against self-proteins with the aid of foreign t-cell epitopes
DK113389D0 (da) Monoklonale antistoffer
DK0687300T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
DK0859957T3 (da) Patientspecifikke immunadsorbenser til ekstraporal apherese og fremgangsmåde til deres fremstilling
BR9306345A (pt) Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
DK0610335T3 (da) Fremgangsmåder til udformning af rekombitope peptider
DK0812206T3 (da) Fremgangsmåde til stimulering af en immunrespons
NO922621D0 (no) Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav
DE60042941D1 (de) Verwendung von anti-cd3 monoklonale antikörper und il-5 zur behandlung von autoimmunkrankheiten
DK0959899T3 (da) LO-CD2a-antistof samt dets anvendelse til h mning af T-celleaktivering og -proliferation
NO173831C (no) Nye monoklonale antistoffer mot IFN-omega, hybridomer til fremstilling derav og anvendelse for rensing samt paavisning eller kvantitativ bestemmelse av IFN-omega, og sett for bruk ved paavisningen
ATE245661T1 (de) Natürliche menschliche igm antikörper
FR2812304B1 (fr) Complexe de lipo-viro-particules, procede de preparation et applications
Ishizaka T cell factors involved in the regulation of the IgE antibody response
DK0597043T3 (da) Porcine adipocytantigener og deres anvendelse til immunologisk bekæmpelse af fedt
UA13922A (uk) Спосіб одержаhhя коhтріhсуліhового фактора, який блокує зв'язуваhhя іhсуліhу з його рецептором та має діабетогеhhу дію
ATE99333T1 (de) Immunogen und seine verwendung zur gewinnung von antikoerpern gegen haemoglobin a1c.
NO952506L (no) Antistoffpreparater mot homogent minaktivin og anvendelse derav for påvisning av minaktivin i humane kroppsvæsker